CN103751757A - Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof Download PDFInfo
- Publication number
- CN103751757A CN103751757A CN201410047621.5A CN201410047621A CN103751757A CN 103751757 A CN103751757 A CN 103751757A CN 201410047621 A CN201410047621 A CN 201410047621A CN 103751757 A CN103751757 A CN 103751757A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- rhizoma
- acute nephritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 131
- 239000000203 mixture Substances 0.000 title claims abstract description 87
- 201000008383 nephritis Diseases 0.000 title claims abstract description 64
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 6
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 6
- 241000931705 Cicada Species 0.000 claims abstract description 3
- 241000555682 Forsythia x intermedia Species 0.000 claims abstract description 3
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 3
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 3
- 239000002775 capsule Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002994 raw material Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 241000206501 Actaea <angiosperm> Species 0.000 claims description 3
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 240000007171 Imperata cylindrica Species 0.000 claims description 2
- 241000545442 Radix Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 47
- 230000002265 prevention Effects 0.000 abstract description 2
- 241001635617 Canscora Species 0.000 abstract 1
- 241000244987 Daiswa polyphylla Species 0.000 abstract 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 241000234435 Lilium Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- 210000004185 liver Anatomy 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- 208000002193 Pain Diseases 0.000 description 23
- 230000036407 pain Effects 0.000 description 21
- 206010030113 Oedema Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000008961 swelling Effects 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 210000003734 kidney Anatomy 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 13
- 230000001225 therapeutic effect Effects 0.000 description 13
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 12
- 208000003251 Pruritus Diseases 0.000 description 11
- 241000894006 Bacteria Species 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 10
- 206010020772 Hypertension Diseases 0.000 description 10
- NZCRJKRKKOLAOJ-XRCRFVBUSA-N rifaximin Chemical compound OC1=C(C(O)=C2C)C3=C4N=C5C=C(C)C=CN5C4=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O NZCRJKRKKOLAOJ-XRCRFVBUSA-N 0.000 description 10
- 229960003040 rifaximin Drugs 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010030302 Oliguria Diseases 0.000 description 9
- 208000004880 Polyuria Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000035619 diuresis Effects 0.000 description 9
- 208000006750 hematuria Diseases 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 206010014025 Ear swelling Diseases 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 206010000087 Abdominal pain upper Diseases 0.000 description 6
- 206010010904 Convulsion Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000001848 dysentery Diseases 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 208000006820 Arthralgia Diseases 0.000 description 5
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 201000007227 lymph node tuberculosis Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 208000004371 toothache Diseases 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010010726 Conjunctival oedema Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 206010034960 Photophobia Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 201000005884 exanthem Diseases 0.000 description 4
- 230000004438 eyesight Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 210000003026 hypopharynx Anatomy 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 206010037844 rash Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010063409 Acarodermatitis Diseases 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 206010001580 Albuminuria Diseases 0.000 description 3
- 206010006002 Bone pain Diseases 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010018498 Goitre Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 241000447727 Scabies Species 0.000 description 3
- 244000296102 Selinum monnieri Species 0.000 description 3
- 235000019084 Selinum monnieri Nutrition 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 206010042674 Swelling Diseases 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000036592 analgesia Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 201000003872 goiter Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 208000001749 optic atrophy Diseases 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 208000005687 scabies Diseases 0.000 description 3
- 210000004706 scrotum Anatomy 0.000 description 3
- 201000009890 sinusitis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010063659 Aversion Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229940097420 Diuretic Drugs 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010015958 Eye pain Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000001408 fungistatic effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 230000002650 habitual effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 208000004396 mastitis Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 235000010603 pastilles Nutrition 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical compound O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 2
- -1 sublimed preparation Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 240000006409 Acacia auriculiformis Species 0.000 description 1
- 241000905376 Actaea dahurica Species 0.000 description 1
- 241000906577 Actaea heracleifolia Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 102100034279 Calcium-binding mitochondrial carrier protein Aralar2 Human genes 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000125183 Crithmum maritimum Species 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010018092 Generalised oedema Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001106041 Lycium Species 0.000 description 1
- 244000241872 Lycium chinense Species 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 1
- 101800000989 Oxytocin Proteins 0.000 description 1
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 241000304447 Sempervivum tectorum Species 0.000 description 1
- 240000005498 Setaria italica Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241001279009 Strychnos toxifera Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000002014 Suppurative Otitis Media Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 229940121792 Thiazide diuretic Drugs 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010043866 Tinea capitis Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 206010044684 Trismus Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 208000012876 acute enteritis Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 208000024783 anasarca Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 108010084210 citrin Proteins 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000021551 crystal sugar Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000022182 gross hematuria Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000003535 nephritogenic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 1
- 229960001723 oxytocin Drugs 0.000 description 1
- 235000002252 panizo Nutrition 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940083618 sodium nitroprusside Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005453 strychnine Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 208000009189 tinea favosa Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine composition for treating acute nephritis and a preparation method thereof. The traditional Chinese medicine composition for treating or preventing acute nephritis comprises the following components: 10-50 parts of fructus forsythia, 10-20 parts of gardenia jasminoides ellis, 5-20 parts of periostracum cicada, 5-15 parts of canscora melastomacea, 5-10 parts of paris polyphylla, 5-15 parts of lily, 5-15 parts of selfheal, 1-10 parts of rhizoma alismatis, 5-15 parts of medlar, 9-15 parts of fructus cnidii, 9-15 parts of ligusticum wallichii, 5-15 parts of radix angelicae, 0.2-9 parts of lalang grass rhizome, 5.5-15 parts of radix paeoniae alba, 6-9 parts of rhizoma zingiberis, and 10-15 parts of liquorice. The traditional Chinese medicine composition has excellent effect on the treatment or prevention of the acute nephritis, is low in drug side effects, and has remarkable clinical popularization value.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of Chinese medicine composition for the treatment of acute nephritis and preparation method thereof.
Background technology
Acute glomerulonephritis is called for short acute nephritis, acute nephritis is that a kind of both sides kidney diffusivity glomerule infringement causing due to allergy after infecting is main acute illness, the feature of primary disease is that onset is more anxious, and after infection, the serial clinical manifestations such as hematuria, albuminuria, cylinderuria, edema, oliguria, hypertension appear in 1-3 week.
Nephritis is the disease that is primary in glomerule.Have clinically acute and chronic two kinds, acute nephritis is more common in child, often betides after infection, common after especially infecting with Hemolytic streptococcus " nephritogenic strains "; Onset is anxious, the course of disease is short, and main manifestations is hematuria, albuminuria, oliguria, edema, hypertension and azotemia, and active treatment is better rear, and minority can develop into chronic nephritis.Nephritis belongs to the traditional Chinese medical science " edema " category in motherland, and some cases " edema " is not obvious, and take hematuria as main, belongs to " hematuria " category in blood disorder.Press the feature of acute nephritis edema, can belong to edema due to wind pathogen, YANG edema class, its morbidity is attacked outward with ailment said due to cold or exposure, fight mutually afterwards in edema due to wind pathogen, or eating and drinking without temperance, the wet dipping of water, or excess of sexual intercourse, the deficiency of YIN is evil excessive relevant, and above-mentioned paathogenic factor can be caused a disease separately, also can hold concurrently and mix as disease, but not from wind, wet, malicious three categories of etiologic factors, relate to lung, spleen, kidney three dirty, when rheumatism poison heresy, to injure lung spleen kidney three dirty, makes lung lose logical tune, spleen loses and transfers, kidney loses folding, and three warmers water channel loses smooth, and functioning of bladder is had no right, and it is wet to cause water, in poison heresy, invade, essence of water and grain runs off in a large number, and occurs clinical all diseases.
Acute renal glomerulus kidney pathological change be that Kidney Volume can compared with normal increases, pathological changes is mainly involved glomerule.Take endotheliocyte and proliferation of mesangial cells as main manifestations, acute stage, can be with neutrophilic granulocyte and monocyte infiltration.When pathological changes is serious, the cell of hypertrophy and infiltration can oppress capillary loops make capillary lumen narrow, even inaccessible, and damage glomerular filtration membrane, can there are hematuria, albuminuria and cylinderuria etc.; And glomerular filtration rate is declined, and there is water-sodium retention, therefore there are clinically edema, oliguria, systemic circulation congestive state as dyspnea, hepatomegaly, venous hypertension etc.
Acute glomerulonephritis treatment:
1, the first-selected penicillin of western medicine 8,000,000 units intravenous drip, 10-14 days, but its essential existing dispute.During symptomatic treatment, for diuresis, detumescence, blood pressure lowering, conventional thiazide diuretic, as Hydrochlorothiazide.When after diuresis, hypertension value is still dissatisfied, can add with calcium channel blocker as nifedipine 20-40mg/d, the oral or vasodilator of gradation is as hydralazine 25mg, every day 3 times.But isokalaemic diuretic (as triamterene and spironolactone) and angiotensin-convertion enzyme inhibitor, should be cautious use of during oliguria, in case bring out hyperkalemia.
2, Chinese medicine: traditional Chinese medical herbal treatment side effect is little, focuses on reparation and the protection of kidney, also has the effect for the treatment of both the principal and secondary aspects of a disease.Primary disease mostly empirical.According to dialectical wind and cold, the wind heat, damp and hot of being divided into, give respectively lung qi dispersing diuresis, the therapies such as removing pathogenic heat from blood and toxic substance from the body.The performance of primary disease convalescent period arteries and veins card is not bery clear and definite, and dialectical difficult grasp, still take clearing away heat-damp and promoting diuresis as main, is helped with yin nourishing, but can not temperature compensation.Anemopyretic: generate heat not aversion to cold, laryngopharynx swelling and pain, edema that face is slight, tongue fur BOHUANG, short urination is red puckery, visible gross hematuria; Rule for the treatment of wind and heat dispersing, removing pathogenic heat from blood and toxic substance from the body.Damp-heat type: can have that heating, dry lip bitter taste, yellow fur, slippery and rapid pulse, oliguria color are red, women's head-ornaments or an anasarca; Rule for the treatment of clearing away heat-damp and promoting diuresis or heat-clearing and toxic substances removing.Wind-cold type: morbidity is anxious, aversion to cold, heating, cough, women's head-ornaments edema, oliguria, hypertension, thin white fur of tongue, floating and tense pulse; Rule for the treatment of freeing lung-Qi and eliminating damp.
At present, the Western medicine for the treatment of acute nephritis is a lot, but most drug therapeutic effect is poor, and also has the shortcomings such as treatment cost is high, side effect is large, even affects patient health when serious.Antibiotic is better to the therapeutic effect of acute nephritis, but antibiotic life-time service can cause human body to produce antibiotic resistance, and the balance of its use meeting destruction intestinal microbial population, has caused serious impact to patient's physical and mental health.In addition, also have the Chinese medicine of a lot for the treatment of acute nephritiss, but the shortcoming such as great majority have that therapeutic effect is poor, cure rate is low and treatment cycle is long.The object of the invention is to provide a kind of effect comprehensively, the Chinese medicine composition of the treatment acute nephritis that clinical effectiveness is good.
Make a general survey of the research direction of world's new drug, be mainly single chemicals and preparations thereof of research and development the eighties in the past, starts to develop biotechnology and natural medicinal plants after the eighties, and drug research direction is tending towards multiformity.In conjunction with modern Chinese medicine theory of development, from improving the angle of curative effect of medication, reduction side effect, through Chinese medicine ingredients being screened to the preparation that extraction and/or compatibility make, its side effect is little, safe, has the advantage that chemical synthetic drug can not be compared.
Summary of the invention
In prior art, chemicals is cured the symptoms, not the disease, and easily damages gastrointestinal tract mucously, and poisonous side effect of medicine is large, and Chinese medicine exists uncertain therapeutic efficacy fixed, lacks relative medicine preparation.Large in order to overcome existing acute nephritis chemotherapeutic agent toxic and side effects, acute nephritis therapeutic effect is difficult to lasting prior art deficiency, the invention provides a kind of Chinese medicine composition for the treatment of acute nephritis, this Chinese medicine composition good effect, side effect is little, it is mainly made by following raw material: Fructus Forsythiae 10-50 part, Fructus Gardeniae 10-20 part, Periostracum Cicadae 5-20 part, Luo Xing grass 5-15 part, Rhizoma Paridis 5-10 part, Bulbus Lilii 5-15 part, Spica Prunellae 5-15 part, Rhizoma Alismatis 1-10 part, Fructus Lycii 5-15 part, Fructus Cnidii 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, Rhizoma Imperatae 0.2-9 part, Radix Paeoniae Alba 5.5-15 part, Rhizoma Zingiberis 6-9 part, Radix Glycyrrhizae 10-15 part.
Fructus Forsythiae: bitter in the mouth; Cold nature.Enter lung; The heart; Gallbladder meridian.Heat-clearing and toxic substances removing; Dispersing swelling and dissipating binds.Cure mainly anemopyretic cold; Epidemic febrile disease; Pyretic stranguria urine retention; Carbuncle; Toxic swelling; Scrofula; Goiter; Sore throat.< < Sheng Nong's herbal classic > > carries: " main cold and heat, scrofula, scrofula, carbuncle malignant boil, goiter, stagnation of pathogenic heat." clinic study shows; Fructus Forsythiae has broad-spectrum antibacterial action; staphylococcus aureus, Hayes dysentery bacterium are had to very strong inhibitory action; other pathogenic bacterium, influenza virus, fungus are had to certain inhibitory action; contained oleanolic acid has heart tonifying, diuresis and hypotensive activity; Citrin can reduce vascular permeability and fragility, prevents haemolysis, also has in addition that tell in antiinflammatory, town, anti-liver injury effect.
Fructus Gardeniae: sweet, hardship, cold.Return liver, gallbladder, stomach warp.Clearing away heat-damp and promoting diuresis, cooling blood for hemostasis.Main icterohepatitis, dysentery, nephritis, the high heat of flu, spits blood, epistaxis, urinary tract infection, oedema due to nephritis, mastitis, acute toothache, sore and toxic, traumatic injury.
Periostracum Cicadae: sweet in the mouth; Salty; Cool in nature.Enter lung; Liver Channel.Dispelling wind-heat; Rash sore-throat relieving; Removing nebula to improve visual acuity; Expelling wind and relieving convulsion.Cure mainly anemopyretic cold; Laryngopharynx swelling and pain; Cough hoarseness; Stupid rash is not saturating; Rubella pruritus; Conjunctival congestion cataracta; Infantile convulsion is twitched; Tetanus.< < detailed outline > > carries: " control phlegm-accumulating vertigo, skin wind heat, varioliform exanthema is had an itch, tetanus and treatment toxic swelling tumor, adult's aphonia, children's's lockjaw sky hangs, the frightened night cry of crying, swelling of the vulva." modern medicine study confirms; Periostracum Cicadae has obvious convulsion, sedation, can block parasympathetic conduction on neck, is widely used in treating that tetanus, chronic Herba Urticae Cannabinae are examined, suppurative otitis media, vasodilation; also have in addition cough-relieving to cough, the particularly effect of coughing of itching of the throat.
Luo Xingcao: hardship, cold.Heat-clearing and toxic substances removing, eliminating stasis to stop pain.Cure mainly hepatitis, nephritis, acute enteritis, dysentery, tonsillitis, injury and bone fracture, arthralgia.
Rhizoma Paridis: cold nature, bitter in the mouth; Slightly poisonous.Enter Liver Channel.Heat-clearing and toxic substances removing, reducing swelling and alleviating pain, cool liver arresting convulsion.Make in furuncle swollen carbuncle, laryngopharynx swelling and pain, venom, fall and flutter the pain of injury, convulsion with spasms.< < Compendium of Materia Medica > > carries: " poison of snakeworm, obtains stopping that this controls, therefore have Rhizoma Paridis, sting and stop all names.Chong Tai, three layers, also lobate because of it.”
The traditional Chinese medical science thinks that Bulbus Lilii has the effect of nourishing the lung to arrest cough, clearing away heart-fire for tranquillization, and especially fresh Bulbus Lilii is more sweet delicious.The people that Bulbus Lilii is particularly suitable for foster lung, nourishing the stomach eats, such as the patient of chronic cough, pulmonary tuberculosis, aphtha of the mouth and tongue, xerostomia, halitosis.Bulbus Lilii not only has good nutritious tonifying effect, and for the patient such as deficient syndrome, tuberculosis, neurosis is of great advantage after being ill, various cancers is had to good curative effect.Aspect the prevention and treatment of tumor, Bulbus Lilii is used for treating pulmonary carcinoma, nasopharyngeal carcinoma, skin carcinoma etc.During the symptoms such as, xerostomia weak in the body void that above-mentioned cancer is carried out occurring after radiotherapy, vexed, dry cough expectorant, cook congee together with Semen oryzae sativae with fresh Bulbus Lilii, after calling in again appropriate crystal sugar or Mel, eat, to the reaction of health invigorating, anticancer growth, alleviation radiotherapy, there is good effect.For another example, fresh Bulbus Lilii and white sugar are smash to deposited affected part in right amount altogether,, infiltration person hemorrhage to skin carcinoma ulceration also has certain therapeutical effect.
Spica Prunellae: bitter in the mouth; Pungent; Cold in nature.Return liver; Gallbladder meridian.Liver heat removing and eyesight improving; Powder detoxifcation.Cure mainly corneal nebula photophobia; Ophthalmalgia; Have a headache dizzy; Tinnitus; Scrofula; Goiter; Acute mastitis; Mumps; Carbuncle furuncle and phyma poison; Acute, chronic hepatitis; Hypertension.< < the southern regions of the Yunnan Province book on Chinese herbal medicine > > carries: " liver-wind of dispelling, the network of passing through.Control facial hemiparalysis, row irritability, opens stagnation of liver-QI, only bones and muscles pain, ophthal malgia, loose scrofula, whole body tuberculosis." modern medicine study confirmation, Spica Prunellae has significant blood pressure lowering and antibacterial action.
Rhizoma Alismatis is the tuber of Notes On Alism At Aceae Rhizoma Alismatis.Theory of Chinese medical science thinks that it is cold in nature, has the effect of promoting diuresis to eliminate damp pathogen.Modern medicine study, Rhizoma Alismatis can reduce serum total cholesterol and triacylglycerol content, slows down atherogenesis; Rhizoma Alismatis and preparation modern times thereof are also used for the treatment of auditory vertigo, dyslipidemia, seminal emission, fatty liver and diabetes etc.But Rhizoma Alismatis has liver toxicity, nephrotoxicity, it is improper to take, and can allow liver, kidney occur swelling and other poisoning symptoms.
Fructus Lycii (formal name used at school: Lycium chinense) is the multi-branched shrub plant of Solanaceae Lycium, and high 0.5-1 rice, can reach more than 2 meters during cultivation.All there is distribution both at home and abroad.Fructus Lycii whole body is precious, and bright Li Shizhen (1518-1593 A.D.) < < Compendium of Materia Medica > > records: " spring is adopted Folium Lycii, name day essence grass; Summer picks flowers, name Sempervivum tectorum; Qiu Caizi, name Fructus Lycii; Dong Caigen, name Cortex Lycii ".Fructus Lycii tender leaf also claims Fructus Lycii head, edible or make Fructus Lycii tea.Modern study, Fructus Lycii has the blood glucose of reduction, lipotropy, and can antiatherogenic effect.
Fructus Cnidii is the fruit of samphire cnidium monnieri.Another name: Serpentis rice, Serpentis pearl, Serpentis foxtail millet, cnidium monnieri core, cnidium monnieri reality, gas fruit, Radix Habenariae Dentatae, favus-infected head beggar, wild Fructus Foeniculi.There is warming the kidney to invigorate YANG; Removing dampness and killing parasites; The effect of dispelling wind for relieving itching.Control impotence in male; Scrotum pruritus due to damp pathogen; Woman's infertility; Cold-damp leukorrhagia; Pudendal pruritus swells and ache; Rheumatic arthralgia; Eczema scabies.The Tang Dynasty is infertile for sexual impotence and cold womb.Fructus Cnidii has the merit of warming the kidney to activate YANG, the impotence in male that treatment deficiency of kidney yin causes, and woman's cold womb is infertile, can be equal to use with Fructus Lycii, Semen Cuscutae, Fructus Schisandrae Chinensis, Cortex Cinnamomi, with kidney tonifying, mends fire, supporing yang emerging flaccidity; < < prescriptions worth thousand gold > > controls kidney yang deficiency and coldness, and the Radix Aconiti ball that sexual impotence does not rise, forms with this product compatibility.For man's scrotum pruritus due to damp pathogen, woman's pudendal pruritus leukorrhagia, eczema scabies.Fructus Cnidii can dampness dispel the wind, killing parasites for relieving itching.Control eczema scrotum, woman's pudendal pruritus band is many, can be alone or decoct soup washout with Radix Sophorae Flavescentis, Cortex Phellodendri, Alumen etc.
The pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, the up top, mountain peak that reaches; Enter again blood system, the descending sea of blood that reaches.Blood circulation promoting and blood stasis dispelling effect is extensive, the various diseases of suitable stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.It is the gas medicine in blood that former times people calls Rhizoma Chuanxiong, nearly says the functions such as pungent loose, the resolving depression of its residence, sensible, pain relieving.The pungent temperature rise of this product is loose, and all hyperactivity of YANG due to deficiency of YIN and excessive rising of liver-YANG person should not apply; Menorrhagia, anemia of pregnant woman also avoid use.
The Radix Angelicae Dahuricae, warm in nature, acrid in the mouth is micro-sweet, has expelling wind and removing dampness; Logical surreptitiously pain relieving; The effect of detumescence and apocenosis.Main headache due to common cold; Supraorbital bone pain; Toothache; Nasal obstruction; Nasal sinusitis; Domination of damp pathogen chronic diarrhea; Women leucorrhea; Ulcer sores; Venom.Clinical in headache due to common cold, supraorbital bone pain, nasal obstruction, nasal sinusitis, toothache, leucorrhea, skin infection swells and ache.Also can be used for the cold expelling that induces sweat, wind-expelling pain-stopping, clearing the nasal passage, dampness leukorrhagia stopping, detumescence and apocenosis.Control headache, supraorbital bone pain, toothache, nasal sinusitis, cold-damp stomachache, hemorrhoidal hamorrhage anal fistula, leucorrhea with red and white discharge, ulcer sores, skin pruritus due to dryness, scabies.Rhizoma Atractylodis have drying damp and strengthening spleen, expelling wind and cold, and the effect of improving eyesight, for dampness taste, distension and fullness in the abdomen, cold-damp leucorrhea, damp-warm diseases and damp invasion of lower energizer, foot swelling and pain in knee, flaccidity are soft unable.Control dampness taste, and see the thick disease such as turbid of distension and fullness in the abdomen, inappetence, fatigue and weakness, white and greasy fur, the compatibilities such as normal and Cortex Magnoliae Officinalis, Pericarpium Citri Reticulatae are applied.
Rhizoma Imperatae has another name called Rhizoma Imperatae, Rhizoma Imperatae, Rhizoma Imperatae, for grass family Rhizoma Imperatae belongs to herbaceos perennial.There is cooling blood for hemostasis, the effect of heat-clearing and toxic substances removing.Cure mainly: for spitting blood, hematuria, pyretic stranguria, edema, jaundice, dysuria, calentura excessive thirst, the gastric heat sound of vomiting of vomitting, coughs.
The Radix Paeoniae Alba is the famous traditional parts of generic medicinal plants of China, applicating history is long, and Radix Paeoniae begins to be loaded in the < < of Eastern Han Dynasty Sheng Nong's herbal classic > >, classifies middle product as, note has " main pathogen; Radix Paeoniae Alba stomachache, except arthralgia due to stagnation of blood, broken hard long-pending; cold and heat hernia abdominal mass; pain relieving, diuresis, QI invigorating ".Nourishing blood to suppress the hyperactive liver, slow middle pain relieving, yin fluid astringing is received antiperspirant.Control the breast abdomen pain over the hypochondriac region, dysentery stomachache, spontaneous sweating, fever due to yin deficiency, menoxenia, metrorrhagia, is with inferior disease.Modern pharmacology studies show that, the intestine in vitro of paeoniflorin to Cavia porcellus, rat and in stomach motion, and rat uterus smooth muscle all shows inhibition, and can the caused contraction of antagonism oxytocin; With acetic acid injection in mouse peritoneal, the index using writhing response as pain, paeoniflorin has significant analgesic effect; The caused convulsions of extractum energy antagonism strychnine of Radix Paeoniae; Radix Paeoniae Alba decoct has bacteriostasis to dysentery bacterium in vitro, and preserved material also has inhibitory action to some pathogenic fungus.Paeoniflorin has cooling effect to white mice normal body temperature, and the mice of artificial fever is also had to refrigeration function.Rat experiment metapedes sole of the foot edema is had to antiinflammatory action; Paeoniflorin has inhibitory action to the rat platelet aggregation of adenosine diphosphate (ADP) induction in vitro or during intravenous injection; Paeoniflorin has obvious inhibitory action to irritate the digestive tract in rats ulcer of bringing out due to anxiety.
Rhizoma Zingiberis < < Sheng Nong's herbal classic > > classifies middle product as, and Rhizoma Zingiberis Recens < < Mingyi Bielu > > classifies middle product as.TAO Hong-Jing meaning: " all Rhizoma Zingiberis methods of doing: water logging three days, peeling is put in flowing water six, and more random peeling, then dries, and puts in Porcelain Jar and makes three, is into." Li Shizhen (1518-1593 A.D.) meaning Rhizoma Zingiberis makes it with female Rhizoma Zingiberis Recens, take fair and clear solid person as good, all being used as medicine and Yi Pao use.Rhizoma Zingiberis, for warm spleen sun, is partially controlled spleen-cold syndrome stomachache and has loose bowels.Can promote blood circulation by recuperating depleted YANG again, warming the lung to resolve fluid-retention, with controlling yang depletion syndrome, extremity are fainted contrary, faint pulse being about to disappear, and cold fluid-retention cough with asthma, the cold physique back of the body is cold, the clear rare disease of waiting of abundant expectoration.
Chinese medicine composition of the present invention take except long-pending numbness, dispersing wind and cold, wind-damp dispelling, bone and muscle strengthening are as main standard, has significant antiinflammatory, analgesia and activating blood circulation to dissipate blood stasis effect after Chinese medicine composition combination of the present invention on Chinese medicinal components is selected.The present invention has carried out preferably the parts by weight of above-mentioned all taste Chinese medicine, and preferred condition is the enhancing of medicine to acute nephritis therapeutic effect after Chinese medicine and western medicine compatibility is used.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention is mainly made by the raw material of following weight portion: 30 parts of Fructus Forsythiaes, 15 parts of Fructus Gardeniaes, 15 parts of Periostracum Cicadaes, 10 parts of Luo Xing grass, 8 parts of Rhizoma Paridis, 10 parts of Bulbus Liliies, 10 parts of Spica Prunellaes, 6 parts of Rhizoma Alismatis, 10 parts of Fructus Lyciis, 12 parts of Fructus Cnidiis, 12 parts of Rhizoma Chuanxiongs, 10 parts of the Radixs Angelicae Dahuricae, 5.5 parts of Rhizoma Imperataes, 10 parts of the Radix Paeoniae Albas, 8 parts of Rhizoma Zingiberiss, 12 parts, Radix Glycyrrhizae.
Preferably, Chinese medicine composition of the present invention also further contains 5 parts of Rhizoma Cimicifugaes, 9 parts of Semen Cassiaes.Rhizoma Cimicifugae is the dry rhizome of ranunculaceae plant C.heracleifolia, Cimicifuga Dahurica or Rhizoma Cimicifugae.Another name: all Rhizoma Cimicifugaes, Os Gallus domesticus Rhizoma Cimicifugae, funny face Rhizoma Cimicifugae, big cattle card holder, Radix Longan, hole root of the tooth.There is heat-clearing and toxic substances removing; Deliver rash; The effect of ascending up spleen-Qi and Yang.Spire can be made cold vegetable dish in sauce equally, cooking or staple food dish filling.There is the effect of removing toxic substances, sore-throat relieving, detumescence.Control gastritis, toothache, laryngopharynx swelling and pain, aphtha of the mouth and tongue etc.Semen Cassiae is the mature seed of leguminous plant Semen Cassiae and little Semen Cassiae.There is liver heat removing kidney tonifying, improving eyesight, the effect of diuretic relieving constipation.Cure mainly conjunctival congestion and swelling pain, photophobia tear is many, optic atrohic blindness, nyctalopia, headache and dizzy, poor vision, cirrhotic ascites, dysuria, habitual constipation.External treatment toxic swelling, tinea disease.Effective in cure to wind heat acute conjunctivitis, hypertension, hepatitis, the hard ascites habitual constipation of liver etc.Semen Cassiae is for diseases such as conjunctival congestion and swelling pain, the many tear of photophobia, optic atrophys.Conjunctival congestion and swelling pain, the diseases such as the many tears of photophobia, are disturbing upward of liver-fire, or stop up due to the head in wind heat.Semen Cassiae can be let out clearly liver and gall stagnated fire, again can dispelling wind and heat pathogens, and for controlling conjunctival congestion and swelling pain key medicine.Wind heat person, normal and Periostracum Cicadae, Flos Chrysanthemi are equal to use; Liver-fire person, often joins Radix Gentianae, Radix Scutellariae, Spica Prunellae and is equal to use.How optic atrophy, caused by deficiency of the liver and kindey.Semen Cassiae liver heat removing and improving eyesight, normal and tonic Liver and kidney medicine are equal to use as Semen Astragali Complanati, Fructus Ligustri Lucidi, Fructus Lycii, the Radix Rehmanniae, to control optic atrophy.Semen Cassiae bitter cold enters liver, can clearing away liver-fire, and holding concurrently again can suppressing liver-YANG, controls the headache, dizzy of excessive rising of liver-YANG therefore available, often joins Flos Chrysanthemi, Ramulus Uncariae Cum Uncis, Spica Prunellae etc. medicinal.Semen Cassiae nature and flavor are sweet salty-cold, double enter large intestine channel and can clearing away heat and moistening the bowels relieving constipation, for interior-heat dryness of the intestine, constipation, can be equal to use with Fructus Cannabis, Semen Trichosanthis.
In order to express better Chinese medicine composition of the present invention, Chinese medicine composition of the present invention can be prepared into conventional clinically dosage form.Such as, the preparations such as powderous preparations, powder, pill, sublimed preparation, unguentum, granule, oral liquid, syrup, tablet, capsule.Preferably, Chinese medicine composition of the present invention is prepared into powder, water preparation, tablet or capsule according to conventional preparation technology.
The present invention also provides a kind of preparation method of Chinese medicine composition described above, it mainly comprises following step: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, according to the 4-9 of coarse powder gross weight, doubly adding volumetric concentration is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Those skilled in the art can be at the technical conventional Chinese medicine pharmaceutical dosage form clinically for preparing of this preparation method, as tablet, capsule etc.
The present invention also asks to protect the purposes of above-mentioned Chinese medicine composition in preparation treatment acute nephritis medicine.Pharmaceutical composition of the present invention, when treatment acute nephritis, demonstrates significant anti-inflammatory and antalgic, activating blood circulation to dissipate blood stasis activity.Drug effect embodiment 19 of the present invention shows, with model group comparison, the low middle Senior Three of a Chinese medicine composition of the present invention dosage group all can significantly reduce dimethylbenzene induced mice ear swelling value (
p< 0.01), show that Chinese medicine composition of the present invention has the effect of the mice ear of remarkable inhibition dimethylbenzene induction, and there is significant dose-effect relationship in its reduction effect to ear swelling.Under same experiment condition, positive control drug nephritis peace Capsules group also significantly reduce ear swelling value (
p< 0.05), but its antiphlogistic effects is obviously not as good as Chinese medicine composition of the present invention.Drug effect embodiment 20 of the present invention shows, mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, all be greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate this Chinese medicine composition of the present invention can extend mice to hot plate stimulate add the sufficient response latency, have certain analgesic activity.Under same experiment condition, positive control drug Rifaximin capsule group (
p< 0.05) and nephritis peace Capsules group (1h,
p< 0.05; 2h,
p< 0.01) also significant prolongation mice incubation period of adding foot reaction, have certain analgesic activity.Drug effect embodiment 21 of the present invention shows, model group and normal control comparison, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity all have significantly and increase (
p<0.05).With model group comparison, basic, normal, high each dosage group of the Chinese medicine composition of the present invention all remarkable or utmost point has reduced the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity significantly, reduction amplitude amount effect relationship, wherein high dose there were significant differences (
p<0.05).Under same experiment condition, positive control drug Rifaximin capsule group has also reduced the high cut index of whole blood, the low cut index of whole blood, erythrocyte aggregation index, but it improves effect all not as good as Chinese medicine composition of the present invention to hemorheology index.The result statistics of liver index shows, model group and normal control comparison, and liver index significantly increases.And with model group comparison, basic, normal, high each dosage group of Chinese medicine composition of the present invention significantly reduced liver index (
p<0.01), positive control drug Rifaximin capsule and Chinese medicine composition of the present invention Chinese medicine composition high dose group of the present invention can reduce significantly liver index (
p<0.05), but effect not as good as Chinese medicine composition of the present invention.Embodiment 22 results show, Chinese medicine composition of the present invention all has good fungistatic effect to most pathogenic entero becteria, this shows that Chinese medicine composition of the present invention all has significant therapeutic effect for the acute nephritis of various bacteria or fungus initiation, can play to infectious acute nephritis the effect for the treatment of both the principal and secondary aspects of a disease.And more estimable, in Chinese medicine composition of the present invention, contain plurality of active ingredients, during for acute nephritis treatment of infection, target spot is many, be difficult for produce drug resistance, be significantly better than existing clinical in widely used antibiotics.
In a word, pharmaceutical composition of the present invention, aspect treatment acute nephritis, compared with prior art has following advantage:
1) compared with positive control drug Rifaximin capsule or nephritis peace capsule, pharmaceutical composition Chinese medicine composition of the present invention is not only more remarkable at antiinflammatory and ease pain, and aspect activating blood circulation to dissipate blood stasis, be also significantly better than positive drug, this shows that the present composition has significant synergism in acute nephritis treatment, not only can significantly improve the symptom of acute nephritis, can also delay the development of acute nephritis, contribute to acute nephritis patient's recovery from illness process;
2) compared with the chemotherapeutic agent of current treatment acute nephritis, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, particularly it does not produce any destruction for intestinal mucosa, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, has significantly improved acute nephritis patient's compliance, and has improved patient's quality of life;
3) existing antibiotic medicine acute nephritis initial stage therapeutic effect still can, but along with obvious drug resistance problem all appears in the prolongation for the treatment of time, its therapeutic effect for acute nephritis declines; In Chinese medicine composition of the present invention, contain multi-medicament component, action target spot is numerous, has effectively solved the Commpensation And Adaptation of acute nephritis medicine, its to the therapeutic effect of acute nephritis not because for the treatment of time extend decline.
The specific embodiment
By specific embodiment, further describe the present invention below, the present invention is not limited only to following examples.Within the scope of the invention or not departing from content of the present invention, spirit and scope, change, combination or replacement that the present invention is carried out, be apparent for a person skilled in the art, is all included within the scope of the present invention.
the preparation of Part I Chinese medicinal composition preparation of the present invention and using method thereof
embodiment 1-6 Chinese medicine composition composition powders
table 1 Chinese medicine composition composition powders prescription of the present invention
Embodiment 1 preparation method: get each medical material in compositions, grind to form powdery according to common process, cross 100 mesh sieves, little fire drying is standby.During use, with directly taking after mixing it with water after water dissolution.Embodiment 2-6 preparation method is with embodiment 1.
embodiment 7-12 Chinese medicine composition water preparation
table 2 Chinese medicine composition water preparation prescription of the present invention
Embodiment 7 preparation methoies: get each medical material in prescription, according to conventional decocting for Chinese herbal medicine technological operation, filtering medicinal residues and get final product.When this water preparation (or claiming decoction) is treated for acute nephritis, take 2-3 every day.Embodiment 8-12 preparation method and using method are with embodiment 7.
embodiment 13-18 Chinese medicine composition tablet/capsule of the present invention
table 3 Chinese medicine composition tablet of the present invention/capsule prescription
Embodiment 13 preparation technologies: each traditional Chinese medicine powder of getting recipe quantity is broken into coarse powder, according to 5 times of coarse powder gross weight, adding volumetric concentration is 80% alcoholic solution, reflux, extract, three times, the each 3h of return time, filters filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete; Chinese medical concrete drying, pulverizing are made to dried cream powder, then added conventional adjunct ingredient to utilize prior art to be prepared into tablet or capsule.Embodiment 14-18 preparation technology is with embodiment 13.
part II Chinese medicine composition pharmacodynamic study of the present invention
embodiment 19 Chinese medicine composition xylol of the present invention causes the impact of mice ear
Get 72 of healthy ICR mices, ♀ ♂ half and half, divide 6 groups, 12/group, be model group, Rifaximin capsule (Hainan company limited of SANYE pharmaceutical factory, lower same), nephritis peace Capsules group (Guangxi Wuzhou Pharmaceutical company limited), Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 1) low dose group, middle dosage group and high dose group.1 time/d of every ig administration; Administration 14 d, 60 min after last medicine, evenly smear dimethylbenzene 0.03 mL/ at mouse right ear and only cause swollenly, cut ears and beat auricle and weigh after 2h, calculate ear swelling value (mg).Swelling value=auris dextra weight-left ear weight.
Result show, with model group comparison, the low middle Senior Three of a Chinese medicine composition of the present invention dosage group all can significantly reduce dimethylbenzene induced mice ear swelling value (
p< 0.01), show that Chinese medicine composition of the present invention has the effect of the mice ear of remarkable inhibition dimethylbenzene induction, and there is significant dose-effect relationship in its reduction effect to ear swelling.Under same experiment condition, positive control drug nephritis peace Capsules group also significantly reduce ear swelling value (
p< 0.05), but its antiphlogistic effects is obviously not as good as Chinese medicine composition of the present invention.
the impact of table 4 Chinese medicine composition xylol of the present invention induced mice ear swelling (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
the impact of embodiment 20 Chinese medicine composition of the present invention on mice hot-plate analgesia
1, mice hot plate pain model is made
Body weight 20g left and right female mice is placed on hot plate dolorimeter, screen 90 of qualified ♀ mices and (lick metapedes time < 5 s or > 30 s throw aside, for preventing foot, scald, also should establish deadline, be generally 60s), the incubation period of adding metapedes reaction take mice is as threshold of pain index, get 72 jennies, be divided into 6 groups, 12/group, it is model group, Rifaximin capsule, nephritis peace Capsules group, Chinese medicine composition of the present invention (making by Chinese medicine composition prescription and preparation technology described in embodiment 1) low dose group, middle dosage group and high dose group.Each group is gastric infusion, and 1 times/day, after successive administration 14d, the time that after mensuration last medicine, 60 min, 120 min add foot reaction.
, Chinese medicine composition of the present invention is on licking the impact of foot response latency in mice hot-plate analgesia experiment
Mice licks foot response latency time showing, with model group comparison, after administration after 1h and 2h, be all greater than model group the incubation period that the mice of each administration group of Chinese medicine composition of the present invention is added foot reaction, there is dose-dependence, and be significantly greater than the incubation period of high dose group model group (
p< 0.05).Illustrate this Chinese medicine composition of the present invention can extend mice to hot plate stimulate add the sufficient response latency, have certain analgesic activity.Under same experiment condition, positive control drug Rifaximin capsule group (
p< 0.05) and nephritis peace Capsules group (1h,
p< 0.05; 2h,
p< 0.01) also significant prolongation mice incubation period of adding foot reaction, have certain analgesic activity.The results are shown in Table 5.
table 5 mice lick foot response latency timetable (
)
Note: with model group comparison, *
p< 0.05, * *
p< 0.01.
the improvement effect of embodiment 21 Chinese medicine composition of the present invention to rat blood stasis models
Get healthy SD rat, body weight 180-200g, 70, male and female half and half, by body weight, be divided at random 7 groups: basic, normal, high group of Normal group, model group, Rifaximin capsule group, nephritis peace Capsules group and Chinese medicine composition of the present invention (by Chinese medicine composition prescription and preparation technology described in embodiment 1, making), 10 every group.Gastric infusion, successive administration 14 days, Normal group and model group are to 0.5%CMC, and all the other give corresponding medicine, and dosage is as table 7.
Administration the 13rd day, 14 days, except Normal group, all the other treated animals are pressed 1mg/kg subcutaneous injection adrenalin hydrochloride, and 2 times/day, interval 4h, after injection, 2h puts animal in 4 ℃ of frozen water 15min for the first time.Administration is got 4-5ml blood anticoagulant heparin on the 15th day and is measured blood rheology parameter, gets the liver conversion organ coefficient of weighing.
Result shows, model group and normal control comparison, the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity all have significantly and increase (
p< 0.05).With model group comparison, basic, normal, high each dosage group of the Chinese medicine composition of the present invention all remarkable or utmost point has reduced the low cut index of whole blood, erythrocyte aggregation index, Casson viscosity and plasma viscosity significantly, reduction amplitude amount effect relationship, wherein high dose there were significant differences (
p< 0.05).Under same experiment condition, positive control drug Rifaximin capsule group and nephritis peace Capsules group have also reduced the high cut index of whole blood, the low cut index of whole blood, erythrocyte aggregation index, but it improves effect all not as good as Chinese medicine composition of the present invention to hemorheology index.The result statistics of liver index shows, model group and normal control comparison, and liver index significantly increases.And with model group comparison, basic, normal, high each dosage group of Chinese medicine composition of the present invention significantly reduced liver index (
p< 0.01), positive control drug Rifaximin capsule and Chinese medicine composition of the present invention Chinese medicine composition high dose group of the present invention can reduce significantly liver index (
p< 0.05), but effect is not as good as Chinese medicine composition of the present invention.
table 6 Chinese medicine composition of the present invention on rat blood stasis models blood flow become impact (
)
Note: with normal control comparison, #
p< 0.05, ##
p< 0.01; With model group comparison, *
p< 0.05, * *
p< 0.01.
the impact of table 7 Chinese medicine composition of the present invention on rat blood stasis models liver coefficient (
)
Note: with normal control comparison, ##
p< 0.01; With model group comparison, *
p< 0.05, * *
p< 0.01.
the In Vitro Bacteriostasis experiment of embodiment 22 Chinese medicine composition of the present invention to common intestinal malignant bacteria
1, experiment material and method
The strain that this experiment is used and culture medium are respectively Candida albicans, dysentery bacterium, colon bacillus, proteus vulgaris, Salmonella, shigella dysenteriae, staphylococcus aureus, resistance to methoxy staphylococcus aureus and campylobacter jejuni, clostridium perfringens enterotoxin, nutrient agar (Nat'l Pharmaceutical & Biological Products Control Institute); Opacity tube (Chinese bacterial turbidity standard, the biological combinations calibrating of Chinese medicine institute).
In Vitro Bacteriostasis experiment: 1. prepare pastille agar plate; Tested material is pressed to the culture medium of doubling dilution preparation different pharmaceutical concentration, heating, modulation required pH value separately, 121 ℃ of sterilizing 30 min, are chilled to 45 ℃; Pour into into aseptic flat board (plate d=65 mm, 10 ml/ plates), finally make the extension rate containing tested material stock solution (2g/ml) in culture medium be respectively l:2,1:4 ... 1:1024; Do blank culture medium separately simultaneously; 2. inoculation; Get the bacterium in young age that reaches the third generation, with 0.9% sodium chloride solution, by standard opacity tube corrected concentrations, be respectively the bacterium liquid to be checked of 108 cfu/ml, be inoculated in respectively the agar surface of pastille separately of different doubling dilutions, inoculate parallel point 3 points simultaneously, make at every containing 2 one bacterium liquid.The liquid-drop diameter of each vaccination is 5-8 mm; After vaccination is dry, upset is dull and stereotyped cultivates 20 h observed results (simultaneously doing blank) in 36 ℃ of constant incubators; 3. criterion; Not occur that minimum dilution tested material concentration on the agar plate of bacterium colony is as its minimum inhibitory concentration (MIC); In this experiment, Chinese medicine composition is as shown in table 8 to the minimal inhibitory concentration of each pathogenic strain.
, experimental result and analysis
the minimal inhibitory concentration measurement result that table 8 Chinese medicine composition is lived common pathogen
Result shows, Chinese medicine composition of the present invention all has good fungistatic effect to most pathogenic entero becteria, this shows that Chinese medicine composition of the present invention all has significant therapeutic effect for the acute nephritis of various bacteria or fungus initiation, can play to infectious acute nephritis the effect for the treatment of both the principal and secondary aspects of a disease.And more estimable, in Chinese medicine composition of the present invention, contain plurality of active ingredients, during for acute nephritis treatment of infection, target spot is many, be difficult for produce drug resistance, be significantly better than existing clinical in widely used antibiotics.
the clinical data of embodiment 23 traditional Chinese medicine composition for treating acute nephritis of the present invention:
Case selection: select acute nephritis patient 200 examples in year June in March, 2011 to 2013, wherein male's 95 examples, women's 105 examples; Age 15-73 year, average (34 ± 8) year; All have stomachache, heating, stomachache is positioned under right upper quadrant of the abdomen or xiphoid-process and with nauseating, vomiter's 184 examples, body temperature 37.5-38.9 ℃ person 142 examples; There are jaundice person's 115 examples, neutrophilic leukocyte rising person 168 examples.By table of random number method, be divided into treatment group and each 100 examples of matched group.The no significant differences (P > 0.05) such as two groups of Genders, age, symptom, have comparability.
1, case selection is selected the routine clinical observation of acute nephritis patient 200 that make a definite diagnosis my institute or outer court, and patient is divided into two groups at random.Treatment group 100 examples, wherein child's 58 examples, the age is in 3-8 year, adult's 42 examples, the age is in 27-55 year.Matched group 100 examples, child's 55 examples, the age is in 4-7 year, adult's 45 examples, the age is in 31-58 year.Two groups of qualifications and record of service are basically identical, without significant difference, have comparability.
2, therapeutic process treatment group patient takes medicine of the present invention, treatment group every day 3 times, is grown up each 3, each 1 of child, and serious symptom person, every day 3 times, each 47 days is a course for the treatment of, in 3-6 month, recovers completely.Matched group, according to the acute nephritis of diagnosing out, gives respectively the blue or green enzyme element of intramuscular injection or other effective antibiotics, the quiet note furosemide of severe patient and stable, the treatment meanss such as quiet sodium nitroprusside, phentolamine, within 10 days, be a course for the treatment of, in 5-12 month, just fade away, rehabilitation gradually after minority case 1-2.
Curative effect judging standard: 1. clinical cure: the symptoms such as edema, oliguria, hematuria, hypertension disappear entirely, and lab testing indices is all normal; 2. effective: the symptoms such as edema, oliguria, hematuria, hypertension significantly alleviate, a normally or only a little higher than normal value of every laboratory; 3. effective: the symptoms such as edema, oliguria, hematuria, hypertension are improved, serum urea nitrogen, creatinine clearance rate are stablized, and routine urinalysis is at normal range value; 4. invalid: symptom, sign have no obvious improvement, even worsen or turn operative treatment.
Table 9 Chinese medicine composition of the present invention is for the therapeutic effect of nephritis
Leukocyte number before and after table 10 acute nephritis patient treatment
Claims (6)
1. treat a Chinese medicine composition for acute nephritis, it is characterized in that it is mainly made by the raw material of following weight portion: Fructus Forsythiae 10-50 part, Fructus Gardeniae 10-20 part, Periostracum Cicadae 5-20 part, Luo Xing grass 5-15 part, Rhizoma Paridis 5-10 part, Bulbus Lilii 5-15 part, Spica Prunellae 5-15 part, Rhizoma Alismatis 1-10 part, Fructus Lycii 5-15 part, Fructus Cnidii 9-15 part, Rhizoma Chuanxiong 9-15 part, Radix Angelicae Dahuricae 5-15 part, Rhizoma Imperatae 0.2-9 part, Radix Paeoniae Alba 5.5-15 part, Rhizoma Zingiberis 6-9 part, Radix Glycyrrhizae 10-15 part.
2. the Chinese medicine composition for the treatment of acute nephritis as claimed in claim 1, is characterized in that it also contains the raw material of following weight portion: 9 parts of 5 parts of Rhizoma Cimicifugaes and Semen Cassiaes.
3. the Chinese medicine composition for the treatment of acute nephritis as claimed in claim 1, is characterized in that it is mainly made by the raw material of following weight portion: 30 parts of Fructus Forsythiaes, 15 parts of Fructus Gardeniaes, 15 parts of Periostracum Cicadaes, 10 parts of Luo Xing grass, 8 parts of Rhizoma Paridis, 10 parts of Bulbus Liliies, 10 parts of Spica Prunellaes, 6 parts of Rhizoma Alismatis, 10 parts of Fructus Lyciis, 12 parts of Fructus Cnidiis, 12 parts of Rhizoma Chuanxiongs, 10 parts of the Radixs Angelicae Dahuricae, 5.5 parts of Rhizoma Imperataes, 10 parts of the Radix Paeoniae Albas, 8 parts of Rhizoma Zingiberiss, 12 parts, Radix Glycyrrhizae.
4. the Chinese medicine composition of the treatment acute nephritis as described in as arbitrary in claim 1-3, is characterized in that: it is powder, water preparation, tablet or capsule.
5. prepare the method for the Chinese medicine composition of the treatment acute nephritis as described in claim 1-3 for one kind, it is characterized in that it comprises the following steps: get the above-mentioned Chinese crude drug of recipe quantity and be broken into coarse powder, according to the 4-9 of coarse powder gross weight, doubly adding volumetric concentration is the alcoholic solution of 40%-95%, reflux, extract, three times, return time is 2-5h, filters, filtrate recycling ethanol, cold filtration, washes with water, after being dried, obtains Chinese medical concrete.
6. the purposes of the Chinese medicine composition as described in as arbitrary in claim 1-3 in preparation treatment acute nephritis medicine.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410047621.5A CN103751757A (en) | 2014-02-11 | 2014-02-11 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
| CN201610020129.8A CN105412898A (en) | 2014-02-11 | 2014-02-11 | Application of traditional Chinese medicine composition in preparing acute nephritis |
| CN201610020132.XA CN105597057A (en) | 2014-02-11 | 2014-02-11 | Method for preparing traditional Chinese medicine composition powder for treating acute nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410047621.5A CN103751757A (en) | 2014-02-11 | 2014-02-11 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020132.XA Division CN105597057A (en) | 2014-02-11 | 2014-02-11 | Method for preparing traditional Chinese medicine composition powder for treating acute nephritis |
| CN201610020129.8A Division CN105412898A (en) | 2014-02-11 | 2014-02-11 | Application of traditional Chinese medicine composition in preparing acute nephritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103751757A true CN103751757A (en) | 2014-04-30 |
Family
ID=50519184
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020129.8A Withdrawn CN105412898A (en) | 2014-02-11 | 2014-02-11 | Application of traditional Chinese medicine composition in preparing acute nephritis |
| CN201410047621.5A Pending CN103751757A (en) | 2014-02-11 | 2014-02-11 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
| CN201610020132.XA Withdrawn CN105597057A (en) | 2014-02-11 | 2014-02-11 | Method for preparing traditional Chinese medicine composition powder for treating acute nephritis |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020129.8A Withdrawn CN105412898A (en) | 2014-02-11 | 2014-02-11 | Application of traditional Chinese medicine composition in preparing acute nephritis |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610020132.XA Withdrawn CN105597057A (en) | 2014-02-11 | 2014-02-11 | Method for preparing traditional Chinese medicine composition powder for treating acute nephritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN105412898A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107360A (en) * | 2014-07-30 | 2014-10-22 | 青岛申达高新技术开发有限公司 | Traditional Chinese medicine composition for treating acute nephritis and preparation method of traditional Chinese medicine composition |
| CN104524460A (en) * | 2014-12-24 | 2015-04-22 | 江志鑫 | Pharmaceutical composition for preventing and treating acute nephritis and application thereof |
| CN104771585A (en) * | 2015-04-24 | 2015-07-15 | 王立昌 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085258A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine composition for treating acute nephritis |
| CN101757403A (en) * | 2009-10-28 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
| CN102038882A (en) * | 2009-10-15 | 2011-05-04 | 张红旗 | Traditional Chinese medicine prescription for treating children acute nephritis |
| CN102225167A (en) * | 2011-05-28 | 2011-10-26 | 宫兆荣 | Traditional Chinese medicine composition for treating pediatric acute nephritis and preparation method thereof |
-
2014
- 2014-02-11 CN CN201610020129.8A patent/CN105412898A/en not_active Withdrawn
- 2014-02-11 CN CN201410047621.5A patent/CN103751757A/en active Pending
- 2014-02-11 CN CN201610020132.XA patent/CN105597057A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101085258A (en) * | 2007-06-26 | 2007-12-12 | 北京艺信堂医药研究所 | Traditional Chinese medicine composition for treating acute nephritis |
| CN102038882A (en) * | 2009-10-15 | 2011-05-04 | 张红旗 | Traditional Chinese medicine prescription for treating children acute nephritis |
| CN101757403A (en) * | 2009-10-28 | 2010-06-30 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
| CN102225167A (en) * | 2011-05-28 | 2011-10-26 | 宫兆荣 | Traditional Chinese medicine composition for treating pediatric acute nephritis and preparation method thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104107360A (en) * | 2014-07-30 | 2014-10-22 | 青岛申达高新技术开发有限公司 | Traditional Chinese medicine composition for treating acute nephritis and preparation method of traditional Chinese medicine composition |
| CN104524460A (en) * | 2014-12-24 | 2015-04-22 | 江志鑫 | Pharmaceutical composition for preventing and treating acute nephritis and application thereof |
| CN104771585A (en) * | 2015-04-24 | 2015-07-15 | 王立昌 | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105412898A (en) | 2016-03-23 |
| CN105597057A (en) | 2016-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585433A (en) | Traditional Chinese medicine composition for treating oral ulcer | |
| CN101569739A (en) | Traditional Chinese medicine composition for treating cholecystitis and preparation method thereof | |
| CN106177183A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja, green tea and Folium Mori | |
| CN103751757A (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN102526510A (en) | Chinese composition for preventing and treating duck virus hepatitis | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN104056242A (en) | Traditional Chinese medicine composition for treating acute cholecystitis and preparation method thereof | |
| CN103768570B (en) | A kind of Chinese medicine composition for the treatment of acute cholecystitis and preparation method thereof | |
| CN103550739B (en) | Traditional Chinese medicinal composition for treating acute enteritis and preparation method of traditional Chinese medicinal composition | |
| CN103861041B (en) | A kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof | |
| CN104771585A (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN104042950A (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN103735906A (en) | Chinese herb preparation for treating dry bronchiectasis and preparation method thereof | |
| CN103800877A (en) | Traditional Chinese and western medicinal compound preparation for treating acute gastroenteritis and preparation method thereof | |
| CN104815267A (en) | Traditional Chinese medicine preparation capable of promoting digestion and relieving stasis to treat infantile indigestion with food retention | |
| CN104107360A (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method of traditional Chinese medicine composition | |
| CN104857255A (en) | Traditional Chinese medicine preparation for treating suppurative otitis media and preparation method | |
| CN104906467A (en) | Traditional Chinese medicine composition for treating gout and preparation method | |
| CN104606638A (en) | Medicine for treating damp-heat type acute eczema and preparation method thereof | |
| CN103721153A (en) | Traditional Chinese medicinal composition for resisting swine virus infection | |
| CN103933427A (en) | Pharmaceutical composition for treating nodular syphiloderm and preparation method thereof | |
| CN103585303B (en) | Medicinal composition for treatment of gastric cancer and its preparation method | |
| CN113827686A (en) | Chinese medicinal prescription for resisting and killing cancer tumor cells, various viruses and bacteria | |
| CN104666811A (en) | Preparation method of pepsin treated APR (Anemarrhena, Phellodendrom and Rehmannia) oral liquid | |
| CN103041259B (en) | Chinese materia medica preparation for curing excessive phlegm, cough and respiratory tract infection of children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zheng Mei Inventor after: Lv Yun Inventor after: Zhou Shengyan Inventor before: Liu Xuejian |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140430 |